A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
ApexOnco Front Page
Recent articles
ELVN-001 is made to look more like Terns’ TERN-701.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Early data with the RIPTAC HLD-0915 look competitive.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
